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A prospective validation study in South-West 
Nigeria on caregiver report of childhood 
pneumonia and antibiotic treatment using 
Demographic and Health Survey (DHS) and 
Multiple Indicator Cluster Survey (MICS) questions
Background Childhood pneumonia is the single largest infectious cause 
of death in children under five worldwide. Demographic and Health 
Surveys (DHS) and Multiple Indicator Cluster Surveys (MICS) provide 
health information on care sought for sick children in resource poor set-
tings. Despite not being primarily designed to identify childhood pneu-
monia, there are concerns that reported episodes of “symptoms of acute 
respiratory infection” in DHS and MICS are often interpreted by other 
groups as a “proxy” for childhood pneumonia. Using DHS5 and MICS5 
survey tools, this study aimed to assess how accurately caregivers, report 
of “symptoms of acute respiratory infection” reflect pneumonia episodes 
and antibiotic use in children under five.
Methods Children aged 0 to 59 months presenting with cough and/or 
difficult breathing were recruited from four study hospitals in Ibadan, 
Nigeria from August 2015 to March 2017. Children were assessed us-
ing World Health Organization (WHO) standard criteria by study physi-
cians to identify whether they had pneumonia. Three hundred and two 
matched children in each category of ‘pneumonia’ and “no pneumonia” 
were followed up at home, either two or eight weeks later, using ques-
tions from DHS5 and MICS5 surveys to assess the accuracy of caregiver 
recall of pneumonia.
Results The specificity of DHS5 and MICS5 questions for identifying 
childhood pneumonia were 87.4 (95% confidence interval (CI) = 83.1-
91.0) and 86.1 (95% CI = 81.7–89.8) respectively and the sensitivity of 
questions were 37.1 (95% CI = 31.6-42.8) and 37.1 (95% CI = 31.6-42.8). 
Correct recall of antibiotic treatment was poor (kappa statistic = 0.064) but 
improved with the use of medicine pill boards (kappa statistic = 0.235).
Conclusions DHS5 and MICS5 survey questions are not designed to 
identify childhood pneumonia and this study confirms that they do not 
accurately discern episodes of childhood pneumonia from cough/cold in 
children under five. The proportion of pneumonia episodes appropriately 
treated with antibiotics cannot be accurately assessed using current DHS 
and MICS surveys. If these results are used to guide programmatic deci-
sions, it is likely to encourage overuse and inappropriate prescribing of 
antibiotics for episodes of cough/cold. International agencies who con-
tinue to use these household data to monitor the proportion of children 
with pneumonia who receive antibiotic treatment should be discouraged 
from doing this as these data are likely to mislead national and global 
programmes. Medicine pill boards are used in a number of DHS surveys 
and should be promoted for wider use in national population surveys to 
improve the accuracy of antibiotic recall.
Electronic supplementary material: 
The online version of this article contains supplementary material.
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Childhood pneumonia is the single largest infectious cause of death in children worldwide with an esti-
mated 0.921 [0.812 − 1.117] million deaths in children under five in 2015 [1], equating to about 16% of 
all child deaths globally [2,3]. The majority of pneumonia deaths in children under five occur in low and 
lower-middle income countries in Sub-Saharan Africa and South-East Asia [2]. The goal of the integrat-
ed Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD) is to reduce 
deaths from pneumonia to fewer than 3 per 1000 live births in children under five by 2025 [4]. This in-
volves improving care seeking for children with symptoms of pneumonia, access to health care, treatment 
with appropriate antibiotics where needed, coverage of pneumococcal vaccination and improvement of 
general health & well-being of children in low and lower-middle income countries. Monitoring trends in 
the proportion of childhood pneumonia cases correctly diagnosed and treated with antibiotics is therefore 
a vital element in the planning and monitoring of programmes aimed at controlling childhood pneumonia.
Demographic and Health Surveys (DHS) and Multiple Indicator Cluster Surveys (MICS) are household 
surveys conducted in low and lower-middle income countries every 3-5 years [5,6]. They collect infor-
mation on health and well-being using standardized methods and tools. These are usually conducted on 
households chosen via a multi-stage cluster sampling design to provide a representative sample of the 
country being investigated. DHS and MICS outputs are used for many purposes, including supporting 
the monitoring of population health and health services. These data are particularly valuable in settings 
where routine health information is not available on a wide scale, is inconsistently collected or is unreli-
able [7,8]. DHS and MICS surveys interview caregivers / mothers of children and gather information on 
episodes of various childhood illnesses. These include suspected acute respiratory infections in children 
under five in the household and are based on a two week recall period. DHS and MICS surveys also gath-
er information on reported use of antibiotics for these episodes [5,6]. Correct interpretation of surveys is 
needed to provide child health programmes with useful advice to guide activities. This in turn requires us 
to know the sensitivity and specificity of survey tools for detecting episodes of childhood disease. How-
ever, cross-sectional surveys are known to be prone to information error and bias with the potential for 
non-sampling errors from differing caregiver recall and survey instruments [9].
DHS and MICS surveys enquire about fever, cough, fast breathing with short, rapid breaths or difficul-
ty breathing in the previous two weeks (and whether these were chest-related) [5,6]. DHS and MICS 
now label these as “symptoms of acute respiratory infection”. Despite this clear terminology, there are 
concerns that these episodes are often interpreted by other groups as a “proxy” for childhood pneumo-
nia where only a minority of episodes reported represent true cases. One prospective study in Pakistan 
and Bangladesh found that current DHS and MICS methods discriminate poorly between children cor-
rectly diagnosed with pneumonia and those with cough/cold [10]. The positive predictive value of DHS 
and MICS tools has been estimated to be only 22% in identifying true pneumonia among those with 
reported symptoms of acute respiratory infection [11]. Despite these surveys enquiring about use of an-
tibiotics for symptoms of acute respiratory infection, current survey tools may not provide an accurate 
denominator number of children with true pneumonia episodes to assess the percentage of children 
with pneumonia appropriately treated with antibiotics. Since the DHS and MICS survey data on anti-
biotic treatment relates to this group of children with ‘symptoms of acute respiratory infection’, there is 
a significant risk that any indicator measuring antibiotic treatment coverage for pneumonia may not be 
valid. Furthermore, concerns have been raised about the accuracy of caregiver recall of antibiotic use 
using current methods [10].
Population–based data on the proportion of children with pneumonia that are treated with an antibiotic 
is an important metric for district, national, regional and global monitoring of interventions designed to 
improve appropriate antibiotic treatment (and survival outcomes) for childhood pneumonia. However, 
if this metric is invalid it could lead to incorrect or uninformed programmatic decisions for the deliv-
ery of interventions. We conducted a prospective observational study to assess the validity of DHS5 and 
MICS5 questions in discerning true cases of pneumonia and treatment with antibiotics in the South-
West region of Nigeria, a country with one of the highest numbers of child deaths from pneumonia in 
the world. We also aimed to assess differences in caregiver recall at two and eight week follow up and 
to test if caregiver recall of antibiotic treatment can be improved by use of an additional survey tool (a 
medicine pill board). Our results were compared to the results of a previous study (which investigated 
DHS and MICS survey tools in Asian countries) in order to provide recommendations on the appropri-
ateness of the use of these metrics in the planning and monitoring of health programmes for tackling 
childhood pneumonia.
Caregiver report of childhood pneumonia and antibiotic treatment using DHS and MICS questions
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METHODS
Study sites
From 12 August 2015, patients were recruited from two sites: Out-patients Departments (OPD) of Oni 
Memorial Children’s Hospital, Ring Road and Adeoyo Maternity Teaching Hospital, Ibadan, Oyo State, 
Nigeria. These are the two biggest hospitals with the highest number of paediatric out-patients in this 
State. They are both secondary health facilities that serve patients from all areas of Ibadan with or without 
being referred. Ibadan is the third most populous city in Nigeria and was chosen as the study site given 
that no similar study had been conducted in an urban African city. When it became increasingly evident 
that the estimated sample size of 300 each of pneumonia and ‘no pneumonia’ cases would likely not be 
achieved within a proposed one year study period we enrolled cases from two additional hospitals; Our 
Lady of Apostle, Catholic Hospital, Oluyoro (a mission secondary health facility) and University College 
Hospital (a tertiary hospital with OPD) in Ibadan. This additional recruitment occurred from 14 April 2016 
until the end of the study which was on 17 March 2017, giving a total recruitment period of 19 months.
Study population
Children aged 0 to 59 months who present to the out-patient departments of the above hospitals suffer-
ing from cough and/ or difficult breathing and their mothers/caregivers.
Study design
This was a prospective observational study to validate pneumonia diagnosis and recall of antibiotic treat-
ment by caregivers. Two groups of children with acute respiratory symptoms - those who were confirmed 
to have pneumonia and those who did not have pneumonia according to WHO algorithms [11] for di-
agnosing clinical pneumonia - were identified, recruited and followed up at home. Clinical diagnosis of 
pneumonia by a study physician using the WHO clinical criteria for childhood pneumonia and verifica-
tion of antibiotic prescriptions by study physicians were used as the gold standard for measuring the ac-
curacy of DHS5 and MICS5 questionnaires [11,12]. Caregivers were surveyed to assess the accuracy of 
their recall of the diagnosis and treatment provided using DHS5 and MICS5 questionnaires. Caregivers 
were followed up after being randomly assigned to either two or eight weeks follow up after recruitment. 
This was done so as to assess whether increasing the length of the recall period from the two week recall 
currently used in DHS and MICS surveys for symptoms of acute respiratory infection would decrease 
the accuracy or validity of caregiver report. Follow-up enabled an assessment to be made of the degree 
to which DHS and MICS measures of antibiotic treatment in those with reported symptoms of acute re-
spiratory infection were valid measures of the antibiotic treatment of true pneumonia in a study popu-
lation. Doctors, trained in the use of survey tools, interviewed the caregiver of each child in their home 
using DHS5 and MICS5 questionnaires and initially without, and then with a paper-based “medicine pill 
board”, which is a novel alternative tool using visual cues to assist in recalling antibiotic use. A WHO staff 
member with substantial experience in training for pneumonia diagnosis and management, Dr S.A. Qazi, 
visited the study sites on two occasions: first, before enrolment started and second, toward the middle 
of the study period on May 29 to June 3, 2016 to monitor the conduct of and progress with the study.
Sample size calculation
Based on baseline estimates of a sensitivity of 60%–70% and specificity of 70%–90% from a previous 
study [10] of mother/caregiver recall of symptoms of acute respiratory infection in predicting true pneu-
monia, it was estimated that 300 children under five years with physician-diagnosed pneumonia and 300 
with “no pneumonia” should be enrolled in order to estimate sensitivity and specificity with a precision 
of +/− 5%. The primary caregivers who were the mothers of these children in virtually all the cases were 
first interviewed using the DHS5 and MICS5 questions relating to pneumonia either at two weeks (200 
with pneumonia and 200 with cough or cold) or eight weeks (100 with pneumonia and 100 with cough 
or cold) after diagnosis.
Selection criteria
Inclusion criteria:
1.  Children aged 0 to 59 months who present to the out-patient departments of the above hospitals 
suffering from cough and/or difficulty breathing and
2.  Mother/ Caregiver willing to sign informed consent form.
Ayede et al.
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Exclusion criteria:
1. Children presenting primarily with an episode of recurrent wheeze or asthma.
2. Children who have pneumonia with danger signs, severe enough to require hospital admission.
3. Children who have symptoms of more than 4 weeks’ duration.
4.  Children who have previously come to the same health facility for treatment of the same illness 
episode and have already been enrolled in the study.
5. Children having history of recent pneumonia episode within past 10 days.
6. Children with history of congenital heart disease (suspected or confirmed).
7.  Children who live outside Ibadan (for appropriate follow-up, only children living within the Ibadan 
Metropolis were enrolled.
8. Children whose mother/ caregiver does not give consent.
Enrolment and data collection
The sequence of recruitment of these children in the outpatient departments was as follows:
•  Children were first registered at the OPD medical record section. All children aged 0-59 months 
were then referred to OPD.
•  The regular OPD physicians examined and prescribed treatment to all these children. Children with 
cough and/or difficulty breathing were then referred to the research study physicians.
•  The study physician then re-evaluated these children and confirmed that the child actually had 
pneumonia or not (according to the WHO guidelines on diagnosis of clinical pneumonia [12]). 
They then confirmed children matched the selection criteria.
• An informed written consent to participate was then taken from the caregivers.
•  The study physician then proceeded with the enrolment. Baseline forms which included all their 
personal details were filled out for the recruited children.
Sampling technique
The follow-up sequence of two and eight weeks was administered randomly in a ratio 2:1. A comput-
er generated randomized scheme was used for this purpose. The list was generated by the data manager 
and kept by the project manager. The project manager maintained a follow-up calendar and informed 
the study physicians of the follow-up schedule.
Case matching
Matching of pneumonia cases with no pneumonia cases was done using a procedure similar to that in a 
Bangladesh and Pakistan study [10]. Matching was performed after enrolment and follow-up of partici-
pants in the study. Pneumonia cases were matched with “no pneumonia” cases at the end of the study in 
order of preference as follows:
1.  Matched on case’s sex, age (±2 months) and week of follow-up and assessed by the same study 
physician.
2.  Matched on case’s sex, age (±2 months) and week of follow-up and assessed by different study 
physician.
3.  Matched on case’s sex, age category (≤12 months or >12 months) and week of follow-up and as-
sessed by the same or different study physician.
If more than one child with “no pneumonia” was found for a case (pneumonia), we randomly selected 
only one control using a Microsoft Excel generated random number.
DHS and MICS questionnaires and alternative measurement tools
DHS5 and MICS5 surveys both have an algorithm of questions about the presence or absence of specific 
signs and symptoms of “symptoms of acute respiratory infection” in DHS and MICS questionnaires [5,6] 
(Questions relating to ‘symptoms of acute respiratory infections’ have changed in subsequent iterations of 
DHS and MICS survey tools since DHS5 and MICS5). Questions ask about the presence of cough, faster 
Caregiver report of childhood pneumonia and antibiotic treatment using DHS and MICS questions
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breathing than usual, short, rapid breaths and difficulty breathing as well as whether caregivers thought 
difficulty breathing was due to a problem in the chest or to a blocked or runny nose. Questionnaires used 
during the study are included in Appendix S1 in Online Supplementary Document.
The presence of fast breathing classifies patients as having ‘symptoms of acute respiratory infection’ in 
algorithms for DHS and MICS. These questions are similar but not identical with differences in wording 
and skip patterns between DHS5 and MICS5 [5,6].
An additional study tool using a drug chart prepared to document drugs which are commonly used in 
and around Ibadan to treat pneumonia, malaria and other common childhood febrile illnesses was em-
ployed. Pictures were also taken of the individual pills/syrups/injections available in the market, which 
were then loaded onto the study personal computer (PC) and printed in the form of a “medicine pill 
board” which the study physician carried during all house visits. Individual home follow-up interviews 
either at 2 weeks or 8 weeks were held with mothers/caregivers of children recruited from the hospital 
OPD. During these interviews, caregivers were initially asked about the use of drugs without showing the 
“medicine pill board” and then were shown the drug chart to assess: how well they recognized the drugs 
used for their children, whether the drugs included in the drug chart were used, and whether any addi-
tional drugs mentioned by the caregivers that were not included in the list of the “medicine pill board”.
Statistical analysis
Descriptive statistics were used to assess the socio-demographic and clinical characteristics of the study 
children.
Sensitivity and specificity were calculated to assess the discriminative ability of each measurement tool 
(DHS5, MICS5, medicine pill board) that was used to reach a decision on the presence or absence of true 
pneumonia, with the area under the curve (AUC) of a receiver operating characteristic (ROC) curve pre-
sented as a summary of both sensitivity and specificity. Clinical diagnosis of pneumonia by a study phy-
sician using the WHO clinical criteria for childhood pneumonia and verification of antibiotic prescrip-
tions by study physicians were used as the gold standard to compare with caregiver recall of pneumonia 
identification and antibiotic treatment. Positive predictive and negative predictive values are presented 
to illustrate the discriminative ability of the questionnaires to accurately determine pneumonia and “no 
pneumonia” respectively. Reported use of antibiotics with and without use of the ‘medicine pill board’ 
were then compared to the treatment recorded as given to calculate the sensitivity and specificity of ques-
tions in accurately recalling antibiotic use. The kappa statistic was used to assess the level of agreement 
between caregiver reports of antibiotic use and recorded treatment given. Associations in cross-tabula-
tions are calculated with the χ2 test or, when expected counts are small, Fisher Exact test. All analyses 
were completed using STATA version 13 (Stata Corp, College Station, TX, USA), with the assumption of 
a P value <0.05 as statistically significant.
Ethics statement
Ethical approval was obtained from the University of Ibadan/University College Hospital Ibadan Insti-
tutional Review Board, Oyo State Research Ethical Review Committee, Ministry of Health, Secretariat, 
Ibadan and the WHO Ethics Review Committee. We employed a two stage written consent procedure: 
caregivers were informed about the study and permission was obtained first at the time of diagnosis and 
enrolment from the hospital, and then again at the start of the follow-up home interviews.
RESULTS
Enrolment and follow-up
From 12 August 2015 – 17 March 2017, 959 patients were enrolled with 665 patients completely fol-
lowed-up. Of these patients, there were 305 with pneumonia, in which 219 and 86 had follow-up at 
two and eight weeks respectively. There were 360 with ‘’no pneumonia” (cough and/or difficult breath-
ing) where 247 and 113 were followed-up at two and eight weeks respectively. However, three out of the 
305 eligible and consented “pneumonia” patients were excluded from the database during matching as 
there were no “no pneumonia” patients that could match them based on age, sex and week of follow-up 
(Figure 1).
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Baseline characteristics of the study children
The socio-demographic characteristics and the clinical features of the matched 302 pneumonia cases and 
302 cases without pneumonia are presented in Table 1. The socio-demographic characteristics of the 
two groups were similar. Expectedly, children with pneumonia had higher respiratory rates than those 
without pneumonia. Fever (axillary temperature ≥37.5°C) occurred more frequently in the pneumonia 
group than the “no pneumonia” group as did crepitations and bronchial breath sounds on chest auscul-
tation (P < 0.001).
Discriminative ability of survey tools
Table 2 shows the sensitivity, specificity, 95% confidence intervals and Area Under the Curve (AUC) for 
ROC curves of the DHS5 and MICS5 tools studied. Data are expressed in percentages including confi-
dence intervals.
Results of the DHS5/MICS5 questions about suspected pneumonia for identifying childhood pneumonia 
shows the poor discriminative power of the survey tools. DHS5 and MICS5 results were similar, although 
their questions are not identical because of some differences in precise wording in the questionnaires and 
skip patterns. The discriminative power of these tools was not significantly different at two and eight week 
follow-up intervals as presented in Table 2.
Antibiotic recall
92% of pneumonia cases and 84% of children without pneumonia were prescribed antibiotic treatment. 
Among caregivers whose child had pneumonia and were given antibiotics, correct treatment recall was 
63.1% for DHS5 and 61.6% for MICS5 at two weeks follow up and 48.8% for DHS5 and 49.3% for 
MICS5 eight weeks follow-up respectively. Correct recall of antibiotic treatment increased to 88.8% and 
82.3% using drug pillboard at two and eight weeks follow-up respectively (Table 3). Caregivers whose 
child had no pneumonia and were given antibiotics, correct treatment recall was (72.2%, 66.9%) and 
(64.4%, 56.9%) using DHS5 or MICS5 at two and eight weeks follow-up respectively. Correct recall of 
antibiotic treatment increased to 89.4% and 89.0% using drug pillboard at two and eight weeks follow-up 
respectively among this study group (Table 3). The specificity of recall in those who did not receive an 
antibiotic did decrease slightly when pill boards were used for both those with and without pneumonia. 
However, the overall level of agreement, as measured by the kappa statistic, indicates that pill boards im-
proved correct recall of antibiotic treatment.
Figure 1. Enrolment and randomization of study patients.
Caregiver report of childhood pneumonia and antibiotic treatment using DHS and MICS questions
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Table 1. Baseline characteristics of the study children*
CharaCteristiCs Pneumonia n = 302 (%) no Pneumonia n = 302 (%) P-value (χ2 test)
Age of child (months) (mean ± SD) 13.84 ± 12.06 15.92 ± 13.68 0.049
Age category of child (months):
0 to 1 22 (7.28) 33 (10.93) 0.165
2 to 11 141 (46.69) 123 (40.73)
12 to 59 139 (46.03) 146 (48.34)
Gender:
Male 168 (55.63) 168 (55.63) 1.000
Female 134 (44.37) 134 (44.37)
Siblings:
No siblings 95 (31.46) 109 (36.09) 0.228
One or more 207 (68.54) 193 (63.91)
Age category of mothers (years):
≤30 119 (39.40) 130 (43.05) 0.363
>30 183 (60.60) 172 (56.95)
Mother’s education:
None/primary 15 (4.97) 20 (6.62) 0.389
Secondary 110 (36.42) 96 (31.79)
More than secondary 177 (58.61) 186 (61.59)
Father’s education:
None/Primary 9 (2.98) 8 (2.65) 0.421
Secondary 88 (29.14) 103 (34.11)
More than secondary 205 (67.88) 191 (63.25)
Father’s occupation status
Unemployed 7 (2.32) 7 (2.32) 1.000
Employed 295 (97.68) 295 (97.68)
Residence:
Rural 56 (18.54) 62 (20.53) 0.538
Urban 246 (81.46) 240 (79.47)
Symptoms:
Fever 194 (64.24) 144 (47.68) <0.001
Cough and cold 301 (99.67) 299 (99.01) 0.624
Catarrh (running nose) 195 (64.57) 224 (74.17) 0.010
Respiratory problem† 29 (9.60) 15 (4.97) 0.028
Gastrointestinal upset‡ 5 (1.66) 6 (1.99) 0.761
Diarrhoea 13 (4.30) 10 (3.31) 0.524
Vomiting 10 (3.31) 10 (3.31) 1.000
Other§ 14 (4.64) 20 (6.62) 0.289
Respiratory rate/min (mean ± SD):
0 to 1 months 59.95 ± 13.92 50.00 ± 6.42 0.007
2 to 11 months 56.92 ± 9.25 40.95 ± 5.80 <0.001
12 to 59 months 49.20 ± 8.80 33.26 ± 5.35 <0.001
Temperature (°C):
<37.5 213 (72.70) 243 (88.04) <0.001
≥37.5 80 (27.30) 33 (11.96)
Finding on auscultation:
No significant findings 201 (66.56) 298 (98.68) <0.001
Significant findings¶ 101 (33.44) 4 (1.32)
*Data collected by study physicians at enrolment.
†Respiratory problem – fast breathing; difficulty in breathing; nasal discharge; blocked nose; chest indrawing; grunting; sneezing.
‡Gastrointestinal upset – abdominal pain; poor appetite; poor feeding; oral sore.
§Other – body rash; abdominal rash; ear discharge; ear pain; recurrent boil; bilateral conjunctival redness.
¶Significant findings – crepitations; bronchial breath sounds; wheeze.
Table 2. Discriminative power of DHS5/MICS5 questions for identifying childhood pneumonia (based on two and 
eight week recall)
reCall Period diagnostiC validity dhs5 Questions area under the Curve* miCs5 Questions area under the Curve*
2 weeks:
Sensitivity 37.33 (30.87-44.13) 61.75 (57.79-65.71) 37.33 (30.87-44.13) 61.06 (57.04-65.08)
Specificity 86.18 (80.86-90.47) 84.79 (79.31-89.29)
8 weeks:
Sensitivity 36.47 (26.29-47.62) 63.53 (57.51-69.55) 36.47 (26.29-47.62) 62.94 (56.83-69.05)
Specificity 90.59 (82.29-95.85) 89.41 (80.85-95.04)
Overall:†
Sensitivity 37.08 (31.62-42.81) 62.25 (58.94-65.56) 37.09 (31.62-42.81) 61.59 (58.23-64.95)
Specificity 87.42 (83.14-90.94) 86.09 (81.67-89.79)
DHS - Demographic and Health Survey, MICS - Multiple Indicator Cluster Survey
* Receiver operator curve. Data are expressed as percentage with 95% confidence interval of percentage.
†Irrespective of the week of follow-up.
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Table 3. Caregiver recall of antibiotic treatment*
reCall Period tool Pneumonia no Pneumonia
Sensitivity (95% CI) Specificity (95% CI) Kappa‡ Sensitivity (95% CI) Specificity (95% CI) Kappa‡
2 weeks:
DHS5 63.13 (56.00-69.86) 61.11 (35.75-82.70) 0.090 72.22 (65.07-78.63) 72.97 (55.88-86.21) 0.316
MICS5 61.63 (53.92-68.93) 66.67 (40.99-86.66) 0.114 66.87 (59.08-74.04) 82.35 (65.47-93.24) 0.316
Pill Board 88.83 (83.58-92.87) 50.00 (26.02-73.98) 0.292 89.44 (84.01-93.52) 69.44 (51.89-83.65) 0.541
8 weeks:
DHS5 48.75 (37.41-60.19) 60.00 (14.66-94.73) 0.019 64.38 (52.31-75.25) 83.33 (51.59-97.91) 0.260
MICS5 49.28 (37.02-61.59) 33.33 (0.84-90.57) -0.028 56.94 (44.73-68.57) 90.00 (55.50-99.75) 0.114
Pill Board 82.28 (72.06-89.96) 40.00 (5.27-85.34) 0.109 89.04 (79.54-95.15) 75.00 (42.81-94.51) 0.545
Overall:†
DHS5 58.99 (52.96-64.83) 60.87 (38.54-80.26) 0.064 69.96 (63.90-75.54) 75.51 (61.13-86.66) 0.298
MICS5 58.09 (51.59-64.39) 61.90 (38.44-81.89) 0.066 63.83 (57.33-69.98) 84.09 (69.93-93.36) 0.279
Pill Board 86.96 (82.40-90.69) 47.83 (26.82-69.41) 0.235 89.33 (84.85-92.85) 70.83 (55.94-83.05) 0.452
CI – confidence interval, DHS – Demographic and Health Survey, MICS – Multiple Indicator Cluster Survey
*Sensitivity and specificity values are expressed as percentage with 95% confidence interval of percentage.
†Irrespective of the week of follow-up.
‡Kappa refers to level of agreement between caregiver reports of antibiotic use through DHS or MICS tools or pill board with antibiotic treatment re-
corded at the hospital.
DISCUSSION
DHS and MICS have a key role to play in providing population-based indicators to guide health pro-
grammes in countries with limited routine health data. However, few studies have evaluated the validi-
ty of DHS and MICS questions for evaluating antibiotic coverage for episodes of childhood pneumonia. 
This prospective observational study in South-West Nigeria adds to evidence from studies in Pakistan and 
Bangladesh [10] and finds similar conclusions in an African setting where malaria is an important child 
health problem and with high child mortality from pneumonia. DHS and MICS surveys are not designed 
to identify pneumonia cases and this study confirms the previous finding from the Asian studies that 
questions used in DHS5 and MICS5 surveys have poor sensitivity and specificity for discerning children 
who have pneumonia from those with no pneumonia. Thus, we suggest that this is a generally applica-
ble finding which reflects the characteristics of the questions and the study populations of these surveys 
and is not related to specific study sites. The proportion of caregivers for children with pneumonia who 
had been treated with antibiotics, accurately recalled this only 58% and 59% of the time with MICS5 and 
DHS5 questions respectively. This recall improved to 87% with the use of a pill board and this should be 
considered as an inexpensive and feasible tool as part of DHS and MICS to improve accurate reporting 
of antibiotic use. Once again, this finding has now been replicated in several study sites and settings [10] 
and we suggest that this may be generally applicable.
Recent progress in improving access to treatment for childhood pneumonia remains a top priority for 
policy makers aiming to decrease preventable child deaths [4]. National programmes require appropri-
ate evaluation measures to assess the prevalence of childhood pneumonia and to subsequently estimate 
the number of cases appropriately treated with antibiotics. Given the limitations of the population-based 
health information in most low-income countries and many lower-middle income countries, key policy 
decisions (especially those requiring population-based data) are often based on DHS and MICS surveys. 
However, on this particular metric, the proportion of children with pneumonia who received antibiot-
ic treatment, DHS5 and MICS5 questions in this Nigerian study had poor sensitivity for identifying true 
pneumonia cases. Comparing this to study sites in Bangladesh and Pakistan, DHS and MICS questions 
in this study had significantly lower sensitivities for detecting true pneumonia (37.3, 95% CI = 30.9-44.1. 
(Table 4). The specificity of DHS5 and MICS5 questions in our study were 87.42 (83.14-90.94) and 
86.09 (81.67-89.79) respectively. These were slightly better than those reported in study sites from Ban-
gladesh and Pakistan (Table 4). However, the respective Area Under the Curve (AUC) estimates which 
summarise discriminative power of this approach in these different settings show that, although individ-
ual sensitivity and specificity values vary across sites, they all fall broadly in the same range of AUC val-
ues (Figure 2). The reasons behind this substantial variation in sensitivity and specificity between coun-
tries and between study sites within countries are unclear and require further investigation. This level of 
unexplained variation is another major reason to urge caution in the use of these data. Differences in this 
Caregiver report of childhood pneumonia and antibiotic treatment using DHS and MICS questions
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Table 4. Specificity and sensitivity of DHS and MICS questions in Bangladesh, Pakistan and Nigeria study sites [10]
study site (number of PartiCiPants) dhs sensitivity miCs sensitivity dhs sPeCifiCity miCs sPeCifiCity
Bangladesh urban (n = 546) 24.6 (17.5-32.9) 25.4 (18.2-33.8) 81.7 (73.6-88.1) 82.5 (74.5-88.8)
Bangladesh rural (n = 455) 71.1 (61.0-79.9) 70.1 (60.0-79.0) 56.5 (45.3-67.2) 56.5 (45.3-67.2)
Pakistan urban (n = 672) 64.7 (58.4-70.9) 63.8 (57.5-70.0) 68.5 (62.5-74.4) 67.2 (61.1-73.2)
Nigeria urban (n = 604) 37.3 (30.9-44.1) 37.3 (30.9-44.1) 86.2 (80.9-90.5) 84.8 (79.3-89.3)
Mean 49.4 49.2 73.2 72.8
DHS – Demographic and Health Survey, MICS – Multiple Indicator Cluster Survey
Figure 2. Receiver Operator Characteristic (ROC) curve of per-
formance in discriminating children with pneumonia across 
four study sites, including Ibadan (Nigeria, urban); other data 
from [10,11].
indicator over time or across countries may be due to arte-
fact based on variation in these underlying parameters rather 
than reflecting any change in antibiotic treatment practices. 
Estimates from these questions therefore should not be used 
to compare pneumonia prevalence or antibiotic treatment 
rates between study sites or countries.
The results of this study demonstrate that population-based 
survey questions to caregivers do not accurately discern true 
pneumonia cases from those with cough/cold (no pneumo-
nia). This is not surprising given that we do not expect care-
givers to be able to know when the symptoms in their child 
represent pneumonia and there is often unreliable and inef-
fective communication on diagnosis between health workers 
and caregivers. Although DHS and MICS report these data 
appropriately there is considerable potential, if reported as 
a proxy for childhood pneumonia, for these data to lead to 
incorrect global and local programme decisions. If we as-
sume an underlying incidence of WHO defined pneumonia 
in developing countries of 0.22 per child per year [14] and 
an under five incidence of acute respiratory infection (ARI) 
in developing countries of 5.5-7.5 episodes per child per year [15-19] then several times more children 
who are identified by these questions about respiratory signs do not have pneumonia than have pneumo-
nia. The recent changes to DHS and MICS questions (which adds specifically whether caregivers thought 
respiratory difficulties were ‘chest-related’) have led to the identification of a sub-group of more severely 
ill children with cough / cold as evidenced by the falling prevalence of these reports over time [20]. Nev-
ertheless, children with pneumonia represent a minority of cases identified. These data should, therefore, 
not be used to estimate burden of pneumonia in young children [2] as they will over-estimate this sub-
stantially and are likely to vary significantly due to varying performance characteristics of this approach 
(as noted above). In addition, these survey questions currently do not provide an accurate denominator 
number of children with true pneumonia and so are severely limited in their ability to estimate appropri-
ate antibiotic coverage for childhood pneumonia. Signs of acute respiratory infection is one of the com-
monest reasons for care seeking and for antibiotic treatment in young children [21]. Use of these data to 
estimate antibiotic treatment rates for child pneumonia can be expected to yield falsely low values and 
may lead to a drive within national programmes to promote and increase antibiotic prescription. This, in 
turn, could contribute to increasing overuse of antibiotics (due to inappropriate antibiotic prescribing for 
episodes of cough/cold) which underlies rising antimicrobial resistance globally.
We found that the use of pictorial representations of locally available treatments (a “medicine pill board”) 
improved accurate recall of antibiotic treatment. This was found consistently in both this study and oth-
er study sites in Pakistan and Bangladesh [10]. Poor antibiotic treatment recall without use of pill boards 
likely underestimates their usage. However, despite an increase in accuracy as measured by the Kappa 
statistic (Table 3), it is noted that there was a decrease in specificity of antibiotic recall. Therefore, further 
research into their use may be warranted but future surveys should consider incorporating similar visual 
cues and a number of DHS surveys have already incorporated their use. Pill boards have been shown to 
improve accurate recall of drugs in other settings [22].
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Use of population-based indicators to measure national programme performance in tackling child 
pneumonia
Given current estimates of pneumonia incidence in developing countries of 0.22 episodes per child per 
year, two week recall surveys will not identify sufficient numbers of pneumonia cases to give accurate 
prevalence estimates unless very large numbers of children are surveyed [14]. This study did not find a 
significant difference in the specificity and sensitivity of survey questions between recall periods of two 
and eight weeks. Inaccurate reporting of childhood diseases may therefore not increase significantly when 
recall is increased by a short period of time [10,23]. Survey recall periods for episodes of acute respirato-
ry infection could therefore be increased without losing quality of data and may capture more episodes 
in a single survey.
Health programmes should explore other avenues to collect health information on childhood pneumonia 
in low and lower-middle income countries. DHS and MICS may be able to provide sufficient informa-
tion on care seeking rates for acute respiratory infections including pneumonia. Other studies could also 
investigate the quality of care from trained providers for childhood pneumonia and prevalence should 
also ideally be based on trained observation for signs of pneumonia and not maternal recall. Approach-
es such as these may provide more accurate measures for the management pathway of childhood pneu-
monia in future [24].
Study limitations
This study is limited by the recruitment of children in hospital out-patient settings since those who sought 
care for their child’s illness may differ systematically from those who did not. Participants were also recruit-
ed from one area of Nigeria and, as has been seen in other studies, the performance of these questions can 
vary significantly by study site [10]. This may mean that the sample in this study is not truly generalisable 
to other children in other areas of Nigeria or, more generally, to low and lower-middle income countries. 
However, the main study conclusions do concur with the findings from study sites in Bangladesh and Pa-
kistan. The recruitment of participants at the time of seeking care and alerting them to follow up may also 
have improved the recall of study participants when followed up subsequently. The same trained doctors 
who were involved in enrolment and diagnosis, also delivered these questions during follow up, which 
may have been a potential source of bias and the use of doctors to deliver questionnaires is different to 
the actual data collectors used in these surveys. There was loss to follow up which was higher in the ‘no 
pneumonia’ group as described in Figure 1. This is a potential source of bias to factor into interpretation 
of results. The specific wording of DHS and MICS questions have also been updated in the most recent 
iteration of surveys. Only a single assessor classified children as having pneumonia or not according to 
current WHO criteria which may have introduced bias when placing child in groups of with or with-
out pneumonia. We attempted to mitigate this by arranging training and monitoring to be conducted by 
a highly experienced WHO staff member who had conducted the training in the previous study [10].
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